Clinical effect of intervention with Gandouling tablets in the perioperative period of splenectomy in patients with Wilson&#39;s disease accompanied by splenomegaly and hypersplenism

Ma ShouLiang; Yang WenMing; Han Hui; Wang YanXin; Dong Ting; Sheng YuQin

doi:10.3969/j.issn.1001-5256.2019.03.028

Volume 35 Issue 3

Mar. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(3): 596-599

PDF( 1976 KB)

Clinical effect of intervention with Gandouling tablets in the perioperative period of splenectomy in patients with Wilson's disease accompanied by splenomegaly and hypersplenism

DOI: 10.3969/j.issn.1001-5256.2019.03.028

Encephalopathy Center, The First Affiliated Hospital of Anhui University of Chinese Medicine

Research funding:

Published Date: 2019-03-20

Abstract

Abstract

Objective To investigate the clinical effect of perioperative Gandouling intervention in patients with Wilson's disease ( WD) complicated by splenomegaly and hypersplenism and the changes in related indices. Methods A total of 60 WD patients with splenomegalyand hypersplenism who were hospitalized in Encephalopathy Center, The First Affiliated Hospital of Anhui University of Chinese Medicine, from July 2016 to July 2018 were enrolled and randomly divided into control group and treatment group, with 30 patients in each group. Thepatients in the control group were given conventional Western medicine treatment including decoppering for 4 courses ( each course of treatmentwas 8 days) , followed by splenectomy and conventional decoppering at the end of week 1 after surgery for 2 courses; the patients in the treat-ment group were given Gandouling in addition to the treatment in the control group. Clinical outcome and changes in 24-hour urinary copper, peripheral hemogram, liver function parameters, and portal venous flow indices were observed. The two independent samples t-test was usedfor comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between twogroups. Results The treatment group had a significantly higher overall response rate than the control group [90% ( 27/30) vs 60% ( 18/30) , χ2= 4. 43, P = 0. 03]. Compared with the control group at the end of two courses of treatment after surgery, the treatment group had sig-nificantly lower 24-hour urinary copper ( t = 41. 07, P < 0. 05) and levels of alanine aminotransferase and aspartate aminotransferase ( t = 7. 29 and 6. 13, both P < 0. 01) and significantly higher levels of red blood cell count, platelet count, and hemoglobin ( t =-5. 49, -3. 43, and-3. 53, all P < 0. 01) . At the end of two courses of treatment after surgery, both groups had a reduction in portal venousflow, and the treatment group had a significantly greater improvement in portal venous flow than the control group ( t = 12. 05, P < 0. 01) .Conclusion Gandouling can improve the clinical outcome of WD patients with splenomegaly and hypersplenism after splenectomy.
- hepatolenticular degeneration,
- splenectomy,
- therapeutics,
- Gandouling tablet

FullText(HTML)

References(13)

References

[1] MA SL, CAI YL, XU L, et al. Treatment of hepatolenticular de-generation with polyene phosphatidylcholine combined withGandouling tablets:A report of 32 cases[J]. Clin J TraditChin Med, 2012, 24 (3) :207-208. (in Chinese) 马守亮, 蔡永亮, 徐磊, 等.多烯磷脂酰胆碱联合肝豆灵片治疗肝型肝豆状核变性32例[J].中医药临床杂志, 2012, 24 (3) :207-208.

[2] CHENG N, WANG K, HU WB, et al. Wilson’s disease in thesouth Chinese Han population[J]. Can J Neurol Sci, 2014, 41 (3) :363-367.

[3] HU WB, HAN YZ, XUE BC, et al. Epidemiological study ofhepatolenticular degeneration at Hanshan County, Ahui Prov-ince[J]. Natl Med J Chin, 2011, 91 (13) :894-897. (inChinese) 胡文彬, 韩咏竹, 薛本春, 等.安徽省含山县肝豆状核变性的流病学研究[J].中华医学杂志, 2011, 91 (13) :894-897.

[4] YANG WM, HAN H, BAO YC, et al. TCM etiology, pathogen-esis and syndrome differentiation and treatment of epatolentic-ular degeneration[J]. J Beijing Univ Tradit Chin Med, 2012, 19 (4) :6-9. (in Chinese) 杨文明, 韩辉, 鲍远程, 等.中医对肝豆状核变性病因病机及辨证论治的探索[J].北京中医药大学学报:中医临床版, 2012, 19 (4) :6-9.

[5] JIANG YP, WANG J, JIANG WW. A new edition of neurologicaldiseases[M]. Shanghai:Shanghai Science Popularization Press, 2014:363-365. (in Chinese) 蒋雨平, 王坚, 蒋雯魏.新编神经疾病学[M].上海:上海科学普及出版社, 2014:363-365.

[6] BAO YC. Contemporaryn neurolgy in Traditional Chinese medicne[M]. Beijing:People's Health Publishing House, 2003:523-527. (in Chinese) 鲍远程.现代中医神经病学[M].北京:人民卫生出版社, 2003:523-527.

[7] SHEN Y, WANG HM. Surgical treatment for Wilson’s diseaseaccompanied by hypersplenia[J]. World J Integr Tradit WestMed, 2003, 12 (9) :910-911. (in Chinese) 沈瑜, 王汉明.肝豆状核变性合并脾功能亢进的外科治疗[J].现代中西医结合杂志, 2003, 12 (9) :910-911.

[8] YANG RM. Hepatolenticular degeneration[M]. Hefei:Anhui Sci-ence and Technology Press, 1995:204-205. (in Chinese) 杨任民.肝豆状核变性[M].合肥:安徽科技出版社, 1995:204-205.

[9] YANG RM. Treatment for Wilson’s disease by drug[J]. JApoplexy Nerv Dis, 2005, 22 (3) :199. (in Chinese) 杨任民.肝豆状核变性药物治疗[J].中风与神经疾病杂志, 2005, 22 (3) :199.

[10] SUN Y, YANG RM. Practical neurology of integrater traditionalChinese and Western Medicine[M]. Beijing:People’s HealthPublishing House, 1999:532-533. (in Chinese) 孙怡, 杨任民.实用中西医结合神经病学[M].北京:人民卫生出版社, 1999:532-533.

[11] YANG RM. Wilson Disease[M]. Beijing:People’s Health Pub-lishing House, 2015:366-367. (in Chinese) 杨任民.肝豆状核变性[M].北京:人民卫生出版社, 2015:366-367.

[12] HAN H, YANG WM, ZHANG J, et al. Characteristics of TCMsyndromes for hepatolenticular degeneration[J]. Clin J TraditChin Med, 2014, 26 (1) :16-19. (in Chinese) 韩辉, 杨文明, 张娟, 等.肝豆状核变性的中医证候特征[J].中医药临床杂志, 2014, 26 (1) :16-19.

[13] LI X, CAI J, XU YW, et al. A case of hepatolenticular degen-eration with hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34 (9) :1967-1971. (in Chinese) 李响, 蔡洁, 徐钰雯, 等.肝豆状核变性合并肝细胞癌1例报告[J].临床肝胆病杂志, 2018, 34 (9) :1967-1971.

Relative Articles

[1]	Zhenglong ZHENG, Xianpeng XU, Baixue LI, Yue SU, Yilan XIE, Quansheng FENG. Influence of splenectomy on the course of liver cirrhosis and related mechanism[J]. Journal of Clinical Hepatology, 2023, 39(8): 1958-1965. doi: 10.3969/j.issn.1001-5256.2023.08.029
[2]	Huimin LI, Yizhuo CHEN, Rui ZHAO, Xiao HUANG, Fei HUANG, Huanhuan LI. A comparative analysis of the hemogram and myelogram of patients with liver cirrhosis and the advantages and disadvantages of splenectomy[J]. Journal of Clinical Hepatology, 2023, 39(9): 2217-2224. doi: 10.3969/j.issn.1001-5256.2023.09.028
[3]	Weiyuan FANG, Yi LU. Diagnosis and treatment of acute liver failure in children with Wilson's disease[J]. Journal of Clinical Hepatology, 2022, 38(2): 268-272. doi: 10.3969/j.issn.1001-5256.2022.02.004
[4]	Wei ZHANG, Jian HUANG, Xiaojuan OU, Jidong JIA. Key points of AASLD practice guidance for the diagnosis and treatment of Wilson's disease (2022)[J]. Journal of Clinical Hepatology, 2022, 38(12): 2709-2711. doi: 10.3969/j.issn.1001-5256.2022.12.006
[5]	Zhaopeng LI, Guangchuan WANG, Chunqing ZHANG. Value of transjugular intrahepatic portosystemic shunt in the prevention of esophageal variceal rebleeding in patients with portal vein thrombosis after splenectomy[J]. Journal of Clinical Hepatology, 2021, 37(6): 1331-1335. doi: 10.3969/j.issn.1001-5256.2021.06.023
[6]	Zhou SiMin, Guo LiPing, Cai WangFeng, Zhou Lu, Wang BangMao. Latest advances in the treatment of hepatolenticular degeneration[J]. Journal of Clinical Hepatology, 2020, 36(1): 218-221. doi: 10.3969/j.issn.1001-5256.2020.01.052
[7]	Lai Li, Peng FangYi, Su Song, Fang Cheng, Zhang MengYu, He Kai, Li Bo, He Pan, Xia XianMing. Clinical effect of robotic versus laparoscopic splenectomy in treatment of nontraumatic splenic diseases:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2281-2285. doi: 10.3969/j.issn.1001-5256.2019.10.030
[8]	Ao Fei, Chen WeiQing. Research advances in portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2018, 34(3): 631-634. doi: 10.3969/j.issn.1001-5256.2018.03.043
[9]	Mou SiYu, Yang Zhe, Wu LiQun, Qiu Xuan, Guo JiaMing. Predictive factors for portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2018, 34(1): 106-111. doi: 10.3969/j.issn.1001-5256.2018.01.022
[10]	Liu ShuMin, Sun Qiu, Zhang MeiJu. Clinical effect on microwave coagulo-necrotic therapy combined with laparoscopic splenectomy in treatment of primary hepatocellular carcinoma complicated by hypersplenism[J]. Journal of Clinical Hepatology, 2018, 34(1): 142-146. doi: 10.3969/j.issn.1001-5256.2018.01.029
[11]	Li ChunXia, Gong JingYu, Zhang MeiHong, Wang JianShe. Effect of pharmacotherapy on decompensated liver function in children with hepatolenticular degeneration[J]. Journal of Clinical Hepatology, 2017, 33(8): 1543-1547. doi: 10.3969/j.issn.1001-5256.2017.08.027
[12]	Fang Feng. Long-term treatment and follow-up management of children with hepatolenticular degeneration[J]. Journal of Clinical Hepatology, 2017, 33(10): 1936-1938. doi: 10.3969/j.issn.1001-5256.2017.10.017
[13]	Mao JiaXi, Zou You, Guo WenYuan. Clinical effect of liver transplantation in the treatment of hepatolenticular degeneration[J]. Journal of Clinical Hepatology, 2017, 33(10): 1977-1980. doi: 10.3969/j.issn.1001-5256.2017.10.026
[14]	Kong DeGang, Lu ShiChun. Effect of splenectomy on liver cirrhosis and related surgical issues[J]. Journal of Clinical Hepatology, 2016, 32(12): 2383-2386. doi: 10.3969/j.issn.1001-5256.2016.12.033
[15]	Tang HanQiu. Clinical effect of laparoscopic splenectomy combined with esophagogastric devascularization in treatment of liver cirrhosis with portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(9): 1743-1746. doi: 10.3969/j.issn.1001-5256.2016.09.022
[16]	He HaiGuan, Shen YiNan, Pang ShuJie, Yang Tian, Lu JunHua. Short-term efficacy of splenectomy versus partial splenic embolization for liver cirrhosis and hypersplenism: a Meta-analysis[J]. Journal of Clinical Hepatology, 2016, 32(2): 301-306. doi: 10.3969/j.issn.1001-5256.2016.02.021
[17]	Zhou JinHang, Wu LiMing, Wang JiangHua, Wang Wei, Ji Lei. Postoperative complications of laparoscopic splenectomy in patients with portal hypertension[J]. Journal of Clinical Hepatology, 2015, 31(11): 1870-1873. doi: 10.3969/j.issn.1001-5256.2015.11.024
[18]	Yang ZhengMao, Zhang LingYi. Risk factors for portal vein thrombosis following splenectomy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(7): 1173-1175. doi: 10.3969/j.issn.1001-5256.2015.07.044
[19]	Wang Wei, Du XiaoNa, Wang JianMin, Zhou LiHong, Zheng HuanWei. Successful antiviral therapy for hepatitis C cirrhosis after partial splenic embolization and splenectomy: a report of one case[J]. Journal of Clinical Hepatology, 2015, 31(11): 1892-1893. doi: 10.3969/j.issn.1001-5256.2015.11.030

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	马守亮，李悦悦，董童雨，戎荣，杨文明，韩辉，盛玉琴. 肝豆汤联合言语训练治疗湿热内蕴型Wilson病构音障碍的临床疗效. 中国实验方剂学杂志. 2024(10): 83-89 .
2.	马守亮，杨文明，韩冰，李悦悦，许志豪，宋成玮，韩辉. 祛瘀化痰法对肝豆状核变性患者神经功能的影响. 中华全科医学. 2022(06): 910-913 .
3.	王丽丽，牛聪影，王燕，孙彩杰，江海林，占婷婷，袁娟，杨杰. 基于CiteSpace中医药治疗肝豆状核变性相关研究的可视化分析. 齐齐哈尔医学院学报. 2022(11): 1052-1057 .
4.	韩冰，马守亮. 肝豆灵片结合西医疗法治疗痰瘀互结型肝豆状核变性吞咽功能障碍30例. 福建中医药. 2022(08): 6-8 .
5.	孙光明，许春生，唐明杰，刘敬华. 精准脾切除术在肝豆状核变性合并脾功能亢进患者中的术后效果. 肝胆外科杂志. 2022(04): 285-287+300 .

Other cited types(7)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1645) PDF downloads(283)

Clinical effect of intervention with Gandouling tablets in the perioperative period of splenectomy in patients with Wilson's disease accompanied by splenomegaly and hypersplenism

DOI: 10.3969/j.issn.1001-5256.2019.03.028